These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33758532)

  • 1. Association of
    Maseng MJ; Tawe L; Thami PK; Seatla KK; Moyo S; Martinelli A; Kasvosve I; Novitsky V; Essex M; Russo G; Gaseitsiwe S; Paganotti GM
    Pharmgenomics Pers Med; 2021; 14():335-347. PubMed ID: 33758532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana.
    Maseng MJ; Tawe L; Thami PK; Moyo S; Kasvosve I; Novitsky V; Essex M; Russo G; Gaseitsiwe S; Paganotti GM
    Medicine (Baltimore); 2022 Apr; 101(17):e29066. PubMed ID: 35512066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
    Heil SG; van der Ende ME; Schenk PW; van der Heiden I; Lindemans J; Burger D; van Schaik RH
    Ther Drug Monit; 2012 Apr; 34(2):153-9. PubMed ID: 22354160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya.
    Ngayo MO; Oluka M; Kwena ZA; Bulimo WD; Okalebo FA
    PLoS One; 2022; 17(3):e0260872. PubMed ID: 35235559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.
    Ramachandran G; Kumar AK; Ponnuraja C; Ramesh K; Rajesh L; Chandrasekharan C; Swaminathan S
    Indian J Med Res; 2013 Dec; 138(6):955-61. PubMed ID: 24521642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
    Reay R; Dandara C; Viljoen M; Rheeders M
    OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana.
    Vujkovic M; Bellamy SL; Zuppa AF; Gastonguay M; Moorthy GS; Ratshaa BR; Han X; Steenhoff AP; Mosepele M; Strom BL; Aplenc R; Bisson GP; Gross R
    J Acquir Immune Defic Syndr; 2017 Aug; 75(4):488-491. PubMed ID: 28481785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon.
    Paganotti GM; Russo G; Sobze MS; Mayaka GB; Muthoga CW; Tawe L; Martinelli A; Romano R; Vullo V
    Infect Genet Evol; 2015 Oct; 35():122-6. PubMed ID: 26247717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
    Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
    Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
    Puthanakit T; Tanpaiboon P; Aurpibul L; Cressey TR; Sirisanthana V
    Antivir Ther; 2009; 14(3):315-20. PubMed ID: 19474465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand.
    Aurpibul L; Chotirosniramit N; Sugandhavesa P; Kosashunhanan N; Thetket S; Supindham T; Piyamongkol W; Supparatpinyo K
    Curr HIV Res; 2012 Dec; 10(8):653-60. PubMed ID: 22950382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.
    Bienvenu E; Swart M; Dandara C; Ashton M
    Antiviral Res; 2014 Feb; 102():44-53. PubMed ID: 24316028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients.
    Swart M; Evans J; Skelton M; Castel S; Wiesner L; Smith PJ; Dandara C
    Front Genet; 2015; 6():356. PubMed ID: 26779253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.
    Dickinson L; Chaponda M; Carr DF; van Oosterhout JJ; Kumwenda J; Lalloo DG; Pirmohamed M; Heyderman RS; Khoo SH
    Antimicrob Agents Chemother; 2014; 58(2):706-12. PubMed ID: 24217698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study.
    Oluka MN; Okalebo FA; Guantai AN; McClelland RS; Graham SM
    AIDS Res Ther; 2015; 12():10. PubMed ID: 25878720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort.
    Ximenez JP; Elias ABR; Nardotto GHB; Barroso PF; Bollela VR; Lanchote VL; Suarez-Kurtz G
    Br J Clin Pharmacol; 2022 Oct; 88(10):4585-4594. PubMed ID: 35514050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
    Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.